

005007-19210500



FIG. 2

009007-19218960




FIG. 3

009007-79648960




FIG. 4

009001-19673960







FIG. 5A-5C

A Vaccine A stimulated line



B Vaccine B stimulated line






FIG. 6A and 6B


A
p117-139 stimulated line



B
p117-139 stimulated clone



C
p6-22 stimulated line



D
p6-22 stimulated clone




FIG. 7A-7D

THE UNIVERSITY OF CHICAGO

21


```

5   10  15  20  25  30  35  40  45  50  55  60  65  70  75
MGSDVRDLNALLPAVSSLGCGGLPVSGAAQWAPVLDFAPPGASAYGSLGGPAPPPAPPPPPPHSFIKQE
.....AAAAAAAAAAAAAAAA.....AAAAA.....AAAAAAAAAAAA.....
.....RRRR.....
.....

80  85  90  95  100 105 110 115 120 125 130 135 140 145 150
PSWGAEPHEEQCLSAFTLHFSGQFTGTAGACRYGPFPGPPPSQASSGQARMFPNAPYLPSCLESQPTIRNQYS
.....AAAA.....AAA.....AAAAA.....
.....RRRR.....RRRR.....
.....DDDDDDDD.....

155 160 165 170 175 180 185 190 195 200 205 210 215 220 225
TVTFDGAPSYGHTPSHHAAQFPNHSFKHEDPMGQCGSLGEQQYSVPPVYGCHTPTDSCGTGSQALLRTPYSSDN
.....AAAA.....AAAAA.....AA
.....RRRR.....
.....DDDDDDDDDDDDDD...

230 235 240 245 250 255 260 265 270 275 280 285 290 295 300
LYQMTSQLECMTNQNMNLGATLKGMAGSSSSSVKWTESQSNHGIGYESDNHTAPILCGAQYRIHGHVFRGIQDV
AAAAAAAA.....AAA.AAA.....AAAAAAAAAAAA
.....RRRRRRRRRR.....RRRR.....RRRR.....
DDDDDD.....DDDDDDDDDDDD.....ddddd.....

305 310 315 320 325 330 335 340 345 350 355 360 365 370 375
RRVSGVAPT LVRSASETSEKRPFMCAYPGONKRYFKLSHLQMSRKHTGEKPYQCDFKDCERRFERSDQLKRHR
AAAAA.AAAAAAAAAA.....AAAA.AAAAAAAAAA.
....RRRRR.....RRRR.....
..DDDDDDDDDDDD.....


380 385 390 395 400 405 410 415 420 425 430 435 440 445 450
RHTGVKPFQCKTCQRKFSRSDHLKTHTRHTGTSEKPFSCRWHSCQKKFARSDELVRHHNMHQRNMTKLHVAL
.....AAAA.AAAA..AA.....AAAA.....AA.....AAAAA.....AAAA.....
.....RRRR..RRRR.....
.....dddddddddd.....

```

FIG. 8B

009001-19248960

A



B




FIG. 9A and 9B




FIG. 10A

00900T "T9E18960




FIG. 10B




FIG. 10C





FIG. 10D

A



B




FIG. 11A and 11B





FIG. 12A and 12B




FIG. 13A-13C

009007 "TSE18960




Fig. 14

009007-1961960




Fig. 15

005007" 19640900




Fig. 16

00500T-1240900




Fig. 17

TABLE 1: Characteristics of Recombinant WT1 Proteins Used for Serological Analysis

| <u>Name</u> | <u>Recombinant Protein</u> | <u>WT1 Amino Acid Position</u> | <u>Molecular Weight</u> |
|-----------------|-------------------------------------|--------------------------------|-------------------------|
| WT1/full-length | Ra12-WT1 full length fusion protein | aa 1-449 | 85kDa |
| WT1/N-terminus | TRX-WT1 N-terminus fusion protein | aa 1-249 | 60kDa |
| WT1/C-terminus | WT1 C-terminus protein | aa 267-449 | 50kDa |

Fig. 18

TABLE 2: WT1 Specific Serum Antibodies in Patients with AML and CML.

| | <u>WT1/full-length</u> | <u>WT1/N-terminus</u> | <u>WT1/C-terminus</u> |
|---------------------------|------------------------|-----------------------|-----------------------|
| Normal Individuals (n=96) | 2/96 (2%) | 1/96 (1%) | 1/96 (1%) |
| AML Patients (n=63) | 14/63 (22%) | 16/63 (25%) | 2/63 (3%) |
| CML Patients (n=81) | 15/81 (19%) | 12/81 (15%) | 3/81 (3%) |

Fig. 19